Long‐term outcome of group D patients with negative serum anti‐<i>Helicobacter pylori</i> antibody and positive serum pepsinogen test in healthy Koreans

Han, Yoo Min; Chung, Su Jin; Choi, Ji Min; Lee, Changhyun; Kim, Sang Woo

doi:10.1111/1751-2980.12660

Cited by 5 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The emission of light was measured by the luminometer, which was related to the presence of anti- Hp IgG in the sample [ 17 ]. Values higher than 1.10 IU/mL were considered positive [ 18 ]. The Hp IgG kit has a sensitivity of 91% and a specificity of 100% [ 7 ].…”

Section: Methodsmentioning

confidence: 99%

The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aim Existing studies have suggested an association between Helicobacter pylori (Hp) infection and nonalcoholic fatty liver disease (NAFLD). We investigated the relationship between Hp infection and NAFLD using controlled attenuation parameter (CAP) and other metabolic factors. Method We conducted a retrospective cohort study of apparently healthy individuals who underwent liver Fibroscan during health screening tests between January 2018 and December 2018. Diagnosis of Hp infection was based on a serum anti-Hp IgG antibody test and CAP values were used to diagnose NAFLD. Results Among the 1,784 subjects (mean age 55.3 years, 83.1% male), 708 (39.7%) subjects showed positive results of Hp serology. In the multivariate analysis, obesity (body mass index ≥25) (odds ratio [OR] 3.44, 95% confidence interval [CI] 2.75–4.29), triglyceride (OR 2.31, 95% CI 1.80–2.97), and the highest tertile of liver stiffness measurement (OR 2.08, 95% CI 1.59–2.71) were found to be associated with NAFLD, defined by CAP ≥248 dB/m, while Hp-seropositivity showed no association with NAFLD. Serum levels of HDL cholesterol significantly decreased in subjects with Hp-seropositivity compared to HP-seronegativity in both groups with and without NAFLD (P<0.001). Conclusion While Hp seropositivity was not associated with CAP-defined NAFLD, serum HDL cholesterol level were negatively associated with Hp-seropositivity in both groups with and without NAFLD. Further clinical and experimental studies are necessary to determine the association between Hp infection and NAFLD.

show abstract

Section: Methodsmentioning

confidence: 99%

The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The HPG kit uses a chemiluminescent enzyme immunoassay, and has sensitivity and specificity of 91% and 100%, respectively [25]. Values higher than 1.10 IU/mL were considered positive [26]. To exclude false negative or positive results for anti- Hp IgG antibody, we reviewed serial changes of the titer in subjects who underwent multiple tests and referred to the results of rapid urease test or histologic examination of gastric tissue, if they were available.…”

Section: Methodsmentioning

confidence: 99%

Association between Helicobacter pylori infection and arterial stiffness: Results from a large cross-sectional study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Chronic systemic inflammation is an important causative factor in the pathogenesis of atherosclerosis. However, the effect of chronic Helicobacter pylori (Hp) infection on arterial stiffness, a predictor of cardiovascular events, remains unclear. We evaluated the association between Hp infection and arterial stiffness in asymptomatic healthy individuals. Methods Arterial stiffness was evaluated using the cardio-ankle vascular index (CAVI). We included subjects who underwent CAVI and anti- Hp IgG antibody evaluations, simultaneously, between March 2013 and July 2017. Demographic characteristics and metabolic and cardiovascular parameters were compared with respect to anti- Hp IgG antibody status. Multivariable logistic regression analyses were performed to determine the effect of Hp -seropositivity and conventional cardiovascular risk factors on arterial stiffness. Results Of 2,251 subjects, 1,326 (58.9%) were included in the Hp -seropositive group. Median age ( P < 0.001) and systolic blood pressure ( P = 0.027) were significantly higher in the Hp -seropositive than in the Hp -seronegative group. Levels of LDL-cholesterol were significantly higher in the Hp -seropositive than in the Hp -seronegative group ( P = 0.016). Other serum metabolic parameters were not significantly different between the two groups. The median CAVI value and the proportion of subjects with a CAVI ≥ 8 were significantly higher in the Hp -seropositive than in the Hp -seronegative group (both P < 0.001). On multivariable logistic regression analyses, Hp -seropositivity, age, body mass index, waist circumference, smoking, hypertension, diabetes mellitus, and dyslipidemia were significantly associated with high CAVI values. In the subgroup analysis conducted according to age group, a tendency towards an increased association between Hp -seropositivity and CAVI was observed with increasing age, even though the difference did not reach the statistical significance. Conclusions Hp -seropositivity was significantly associated with arterial stiffness. Hp infection may contribute to the development of cardiovascular diseases.

show abstract

“…In three of the five studies comparing atrophic versus non‐atrophic gastritis, 8,10–13 higher PgII levels were associated with non‐atrophic gastritis. In a large study by He and coworkers, 8 the status of the gastric mucosa was only assessed endoscopically 14 : patients with both non‐atrophic and atrophic gastritis showed significantly higher PgII serum levels than controls 15 . Taken together, the studies considered suggest that PgII is consistently associated with gastric inflammatory lesions (more than with atrophy).…”

Section: Resultsmentioning

confidence: 99%

“…Overall, the findings of the present review do not alter the skeptical conclusion reached by M. Tarek Al‐Assi in 1999, who wrote: “Despite a significant fall in serum markers of H . pylori infection in the groups of successfully treated individuals, no marker (PgII among others) tested in this study approached the reported accuracy of the urea breath test.” 15 …”

Section: Discussionmentioning

confidence: 99%

Pepsinogen II in gastritis and Helicobacter pylori infection

et al. 2022

View full text Add to dashboard Cite

Background and Aim In the gastric mucosa, pepsinogen II (PgII) is produced/secreted by glands in the mucus‐secreting antral and cardia compartments, but also by the chief cells and the oxyntic glands. Increasing PgII serum levels are associated with the whole spectrum of gastric inflammatory diseases, including gastritis induced by Helicobacter pylori (H. pylori). This review critically addresses the clinical value of PgII serology for assessing gastric mucosal inflammation, and as a marker of H. pylori status, in both H. pylori‐positive patients and after eradication therapy. Results A search in PubMed/Scopus records yielded 39 out of 1190 published scientific studies meeting the selection criteria for this study. In the studies considered, PgII levels were significantly associated with non‐atrophic gastric inflammatory lesions (p‐values: 0.025–0.0001). H. pylori‐positive patients had significantly higher PgII levels than H. pylori‐negative individuals (p‐values: 0.o5–0.0001). While a significant drop in serum PgII levels is consistently reported in H. pylori‐eradicated patients (p‐values: from 0.05 to 0.0001), inconsistencies in the related negative and positive predictive values significantly lower the clinical reliability of PgII testing by comparison with other available non‐invasive tests. Conclusions PgII serology may provide clinically useful information on gastric inflammatory diseases, particularly if they are non‐atrophic. PgII serology is inconsistent, however, for the purposes of distinguishing patients whose H. pylori eradication therapy is successful from those who remain infected.

show abstract

Long‐term outcome of group D patients with negative serum anti‐Helicobacter pylori antibody and positive serum pepsinogen test in healthy Koreans

Abstract: A family history of GC and low baseline PGI/II were independently associated with an increased risk of progression of precursor lesions of GC.

Cited by 5 publications

References 41 publications

The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors

The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors

Association between Helicobacter pylori infection and arterial stiffness: Results from a large cross-sectional study

Pepsinogen II in gastritis and Helicobacter pylori infection

Contact Info

Product

Resources

About